Que Y, et al. - In patients with soft tissue sarcoma treated with pazopanib, sorafenib and sunitinib, researchers intended to determine the frequency of severe adverse effects. A comprehensive search of PubMed, Web of Science, Ovid, the Cochrane Library and Embase databases from the drugs’ inception to May 2017 was performed to identify clinical trials. Compared with sorafenib and sunitinib, pazopanib displayed a higher incidence of all-grade nausea, diarrhea and hypertension. In the current study, statistically significant differences in certain common adverse effects, like all-grade and severe AEs, were noticed among pazopanib, sorafenib and sunitinib. Findings suggested that, in order to avoid unnecessary dose reductions and treatment-related discontinuations, early and prompt management was critically required.